Aix Marseille University

At Aix Marseille University, research in neoplasms and blood cancers focuses on improving outcomes for patients with advanced solid tumors, leukemia, lymphoma, and rare cancer subtypes. These studies are testing new treatment combinations and comparing them with current standards to better control disease and extend survival.

• Advanced solid tumors, including lung, colorectal, pancreatic, ovarian, and head and neck cancers
• Acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies
• Testing new therapies and treatment combinations to improve response rates, survival, and disease control

The site’s oncology portfolio also includes work on biomarker-guided care and personalized treatment strategies, reflecting a strong interest in matching therapy to tumor biology.

Clinical trials in nervous system diseases and brain tumors examine new approaches for glioblastoma, high-grade brain tumors, primary central nervous system lymphoma, and other difficult-to-treat neurologic cancers. The goal is to strengthen treatment effectiveness while also improving disease control and long-term outcomes.

• Glioblastoma and other high-grade brain tumors
• Primary central nervous system lymphoma and recurrent CNS tumors
• Evaluating intensified therapy and novel combinations to improve survival and tumor response

This research area combines cancer care with advanced imaging and neurologic expertise, supporting more precise management of complex tumors.

A major focus at this educational institution is pediatric oncology, with trials in neuroblastoma, Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma. These studies aim to refine treatment strategies for children, adolescents, and young adults with high-risk or relapsed disease.

• High-risk neuroblastoma and relapsed or refractory neuroblastoma
• Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma
• Testing new combinations to improve cure rates and reduce disease recurrence

The research landscape includes both frontline and salvage treatment questions, showing a broad effort to improve care across the full course of pediatric cancer.

Trials in digestive system diseases cover colorectal, rectal, gastric, pancreatic, cholangiocarcinoma, and ampullary cancers. The studies are designed to improve surgery-related outcomes, strengthen systemic treatment, and explore biomarker-driven approaches for selecting the most effective therapy.

• Colorectal cancer, rectal cancer, and metastatic colorectal cancer
• Pancreatic adenocarcinoma, ampullary adenocarcinoma, and cholangiocarcinoma
• Evaluating new combinations, adjuvant strategies, and personalized treatment based on tumor features

The work highlights a strong interest in precision oncology, especially for patients with advanced or hard-to-treat gastrointestinal cancers.

Research in nervous system diseases extends beyond cancer to include stroke, Parkinson’s disease, and amyotrophic lateral sclerosis. These trials aim to evaluate new therapies that may improve symptom control, slow progression, or support recovery after neurologic injury.

• Stroke and intracerebral hemorrhage
• Early Parkinson’s disease and related movement disorders
• Amyotrophic lateral sclerosis and other neurodegenerative conditions

The site’s neurology studies reflect a broad effort to advance both acute and chronic neurologic care through better treatment options and improved clinical outcomes.

Trials in hemic and lymphatic diseases and genetic phenomena address conditions such as sickle cell disease, beta-thalassaemia, hereditary angioedema, and developmental syndromes. The purpose is to improve long-term disease control, reduce complications, and expand treatment options for rare and inherited disorders.

• Sickle cell disease and beta-thalassaemia
• Hereditary angioedema and other rare immune-mediated conditions
• Testing therapies aimed at symptom prevention, safety, and sustained benefit

This research area shows a strong commitment to precision care for patients with uncommon and genetically driven diseases.

Studies in musculoskeletal diseases focus on cancers and growth-related conditions affecting bone and connective tissue, including osteosarcoma, rhabdomyosarcoma, and growth disorders. The aim is to improve treatment effectiveness and support better functional outcomes.

• Osteosarcoma and other bone-associated tumors
• Growth disorders linked to genetic and developmental conditions
• Evaluating therapies that may improve disease control and patient well-being

The site’s work in this area connects oncology, pediatrics, and genetic medicine in a multidisciplinary way.

Clinical research in cardiovascular diseases includes studies on pulmonary embolism and bleeding-related emergencies such as intracerebral hemorrhage. These trials are aimed at clarifying the best treatment approach and improving patient safety in acute care settings.

• Isolated subsegmental pulmonary embolism
• Intracerebral hemorrhage and other urgent vascular conditions
• Assessing whether treatment strategies can improve outcomes while limiting risk

The site contributes to evidence that may guide everyday decision-making in time-sensitive cardiovascular care.

Through its Centre de Résonance Magnétique en Biologie et Médecine, the site also supports research linked to diagnostic techniques and biologic assessment. These studies aim to improve how disease activity, treatment response, and biomarkers are measured across several therapeutic areas.

• Biomarker-based assessment in neurologic and oncologic disease
• Imaging-supported evaluation of treatment response and disease progression
• Improving diagnostic precision and clinical monitoring

This translational focus strengthens the connection between advanced imaging, clinical research, and patient care at Aix Marseille University.